Pfizer

June 15, 2018

Talazoparib, Potential Treatment for Metastatic Breast Cancer with BRCA Mutations, Up for US and EU Approval

News

The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have agreed to review Pfizer’s application for talazoparib, a candidate for the treatment of metastatic breast cancer in patients ... Read more

March 12, 2018March 12, 2018

New Blood Test Quickly Predicts Ibrance Treatment Response in Breast Cancer Patients, Study Shows

News

A new blood test could predict how a patient will respond to metastatic breast cancer medication Ibrance (palbociclib) months earlier than current approaches, a U.K. study suggests. Research shows the ... Read more

December 18, 2017

Talazoparib Prevented Disease Progression in Breast Cancer with BRCA Mutations in Phase 3 Trial

News

Pfizer’s talazoparib prolonged the time until disease progression or death in breast cancer patients with inherited BRCA mutations, compared to standard chemotherapy, in a Phase 3 trial of the treatment. ... Read more

November 17, 2017November 17, 2017

FDA Approves Faslodex in Combo with Verzenio for Women with Advanced Breast Cancer

News

The U.S. Food and Drug Administration (FDA) expanded to use of AstraZeneca’s Faslodex (fulvestrant) to include it in combination with Verzenio (abemaciclib) to treat HR-positive, HER2-negative advanced or metastatic breast ... Read more

November 15, 2017November 15, 2017

European Commission Approves Faslodex-Ibrance Combo for Advanced Breast Cancer

News

The European Commission (EC) has extended the approval of AstraZeneca‘s breast cancer therapy Faslodex (fulvestrant) to be used in combination with Ibrance (palbociclib) for advanced breast cancers. The combination can now be used ... Read more

May 17, 2017May 21, 2020

Phase 2 Trial to Assess EP-101 Cancer Vaccine-Bavencio Combo Therapy in HER2- Breast Cancer Patients

News

EpiThany says it will test its multi-antigen vaccine EP-101 STEMVAC — in combination with the PD-L1 antibody Bavencio (avelumab) — as a neoadjuvant therapy in breast cancer patients, under a three-way agreement ... Read more

February 16, 2015February 16, 2015

FDA Approves Ibrance for Advanced Breast Cancer in Postmenopausal Women

Breast Cancer News, News

Pfizer, Inc. has been granted accelerated approval from the U.S. Food and Drug Administration for its drug Ibrance (palbociclib) for the treatment of advanced metastatic breast cancer. Ibrance is meant to treat postmenopausal ... Read more

December 22, 2014October 18, 2016

Pfizer’s Palbociclib Doubles Progression-Free Survival in Breast Cancer Trial

Breast Cancer News, News

An experimental drug known as palbociclib, developed by Pfizer, Inc. and tested at the Revlon/UCLA Women’s Cancer Research Program in UCLA’s Jonsson Comprehensive Cancer Center (JCCC), extended progression-free survival of ... Read more

October 14, 2014October 16, 2014

Pfizer’s Palbociclib Granted FDA Priority Review For ER+ Breast Cancer Treatment

News

Pfizer Inc. has announced that the New Drug Application (NDA) for palbociclib has been accepted for filing and granted Priority Review by the United States Food and Drug Administration (FDA). ... Read more

August 28, 2014August 28, 2014

Pfizer Enrolls HR+, HER2- Advanced Breast Cancer Patients in Palbociclib Expanded Access Program

Breast Cancer News, News

Pfizer is preparing to initiate a multi-center, open-label expanded access program (EAP) for an investigational treatment for post-menopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) ... Read more